|Articles|January 11, 2023
- Pharmaceutical Executive: January 2023
- Volume 43
- Issue 01
What We Foresee in ’23: Pharm Exec’s Annual Industry Outlook
Exploring the most relevant topics affecting the biopharma industry as the new year gets underway—ranging from trends ripe with risk and opportunity to those driving more definitive growth opportunities in patient care.
Advertisement
Articles in this issue
over 3 years ago
Key Factors Attributing to a Successful Product Launchover 3 years ago
Closing the Digital Gap: FDA’s Oversight of Social Mediaover 3 years ago
Sales-Rep Compensation: Adding Long-Term Incentives to Mixover 3 years ago
Co-creating New Innovationsover 3 years ago
The Potential Impact of the IRAover 3 years ago
Patient Hubs Continue Growthover 3 years ago
Social Media’s Complex Climbover 3 years ago
Industry Workforce Seeks Clarityover 3 years ago
Cybersecurity Threats & PharmaAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Makes Leadership Overhaul Following Commissioner Makary’s Departure: Report
2
The Risks and Benefits of FDA Reviewing Real-Time Data
3
Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates
4
FDA Approves Baxdrostat for Uncontrolled Hypertension in First-in-Class Entry
5